You are here

List of Confirmed Posters

2020 Poster Session: A Virtual Experience
Date of CE Release:  August 25, 2020
Date of CE Expiration:  January 31, 2021
Location: Online

TOTAL OF 58 CONFIRMED POSTERS:

# TITLE OF POSTER Main Author
1 Transcranial Magnetic Stimulation for Neuropathic Pain- An INS/NANS Expert Consensus Panel Review and Recommendation Albert Leung
2 Repetitive Transcranial Magnetic Stimulation (rTMS): A Large-Scale Retrospective Clinical Data Analysis Indicating rTMS as Effective Treatment for Generalized Anxiety Disorder (GAD) Alex Engelbertson
3 Case Study: Preliminary Results of Hypnosis in Conjunction with rTMS for Comorbid Anxiety and Depression Alice Musher
4 Neuronavigation Guided rTMS in Alleviating Gulf War Illness Symptoms Alphonsa Kunnel
6 Anhedonia in Major Depressive Disorder: Can it be the Chicken And the Egg for Transcranial Magnetic Stimulation? Andrew M. Fukuda
7 Initial report on long-term durability of deep TMS for obsessive compulsive disorder Aron Tendler
8 Preliminary characteristic of 45 patient of the study placebo-controlled, randomized, double-blind clinical trial to assess the safety and efficacy of using Deep Transcranial Magnetic Stimulation (EMTp) in smoking cessation Bianca Boura Bellini
10 Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced Therapy Is Low Karen Heart
11 Transcranial Magnetic Stimulation Induces Insomnia; A Case Series Christina Raghunandan
12 Elderly TMS Response and Duration: A 6 Month Study Debra J. Stultz
13 Gender Related TMS Response in Depression and Insomnia Debra J. Stultz
14 A novel Theta Burst Transcranial Magnetic Stimulation (θTMS) protocol to decrease suicidal ideation Mark Xuereb
15 Audio-Guided Mindfulness Meditation During TMS Sessions for the Treatment of Major Depressive Disorder (MDD): A Feasibility Pilot Study Eric Tirrell
16 Outcomes of Ketamine IV Treatments for TMS Therapy Poor Responders Erin Amato
17 Does it Matter if Depressed Patients get TMS Sessions Less Often than 5 Times per Week? A Treatment Schedule Density Analysis Fatih Kokdere
18 Gender Differences in Transcranial Magnetic Stimulation Treatment Outcomes for Major Depressive Disorder: A Single Institution E Ganesh Maniam
19 Real-world efficacy of deep TMS for obsessive-compulsive disorder: interim post-marketing analysis of 192 patients from twenty-two sites Geoffrey Grammer
20 Incidence of side effects in patients receiving Repetitive Transcranial Magnetic Stimulation (rTMS) Harpreet Singh
21 Music and rTMS; Novel combination approach for the treatment of depression Irakli Mania
22 A Study of Bilateral Prefrontal rTMS to Treat the Symptoms of mTBI and PTSD: Preliminary Effectiveness and Tolerability Megan Tsui
23 Two Cycles of rTMS as a Protective Measure Against Early-Onset Alzheimer’s Disease: A Case Report Megan Tsui
25 A systematic review and meta-analysis comparing iTBS to rTMS to sham in randomized controlled trials Jeffrey Voigt
26 Repetitive Transcranial Magnetic Stimulation and migraine: Case Report José Ricardo López Melgar
29 The Efficacy of rTMS with Psychotherapy, Sleep Modifications & Exercise Karan Narwal
31 Therapeutic Efficacy of Off-label TMS Protocol for Posttraumatic Stress Disorder: A Case Study Kimi Hashimoto
32 Bipolar Depressed Patients Respond Better to rTMS Than Unipolar Depressed Patients Larissa Gama-Chonlon
33 Low Frequency (1Hz) dTMS H1 Coil over the Right DLPFC for Late Life TRD: Case Report Lucian Manu
34 Transcranial Magnetic Stimulation for Persistent Post-Traumatic Headache- An INS/NANS Expert Consensus Panel Recommendation Maheen M. Adamson
35 Psychiatric comorbidities did not influence remission and response rates in patients treated with transcranial magnetic stimulation Malik Nassan
36 Repetitive Transcranial Magnetic Stimulation (rTMS) of spinal cord for freezing of gait in Parkinson disease: A Pilot Study Marco Antonio Marcolin
37 Use of Transcranial Magnetic stimulation in treatment resistant depression in MU health care: Effectiveness and outcome Meelie Bordoloi
39 Cortical pain modulatory functional enhancement after rTMS associated with durable headache improvement in mTBI patients Michael Vaninetti
40 The effects of extended rTMS treatment course on response outcome in patients with Major Depressive Disorder - Salience 51 Naima Monira
41 Evaluation of cognitive performance in clinically depressed patients using THINC-it after rTMS treatment Naima Monira
42 MDD Responds Equally to dTMS With and Without Comorbid Personality Disorders Owen Muir
43 Accelerated and Non-Accelerated dTMS Protocols Both Effective in Treatment of MDD Owen Muir
44 TMS Treatment With the H1 Coil in Youth Age 10-21 Effective in Ameliorating MDD Symptoms Owen Muir
47 A Review of Non-Invasive Brain Stimulation for Cognitive Impairment: Evidence for Expansion of Clinical Indications Pranav Jagtap
48 Case Study: Treatment of Pediatric OCD with rTMS Priya Parmar
49 A retrospective outcome study comparing the effectiveness of rTMS therapy provided 3 versus 5 treatments per week. Randy Pardell
50 Bilateral rTMS Shows No Advantage in Depression nor in Comorbid Depression and Anxiety: A Large Naturalistic Study Rebecca Mae Allen
51 Cost-Effectiveness of TMS in Managing Neuropathic Pain (NP) and Co-Morbid Depression Richard A. Bermudes
52 Outcomes of Standard TMS Treatment Compared to Theta Burst Protocol for MDD in a Naturalistic Setting Rick Trautner 
Derek Schumm
53 What is the durability of deep TMS for major depressive disorder? Roman Gersner 
54 Cognitive Training During TMS Does Not Improve Depression Outcomes Sandeep Vaishnavi
55 A Cognitive Biomarker May Optimize TMS Depression Outcomes Sandeep Vaishnavi
60 Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospe Steve Best
61 Deep TMS for major depression, interim post-marketing analysis of 1040 patients Steven A. Harvey
62 Safety of TMS Treatment up to 140% of Motor Threshold Todd Hutton
63 Comparison of Naturalistic Treatment Outcomes with the Standard 38-Minute Protocol vs. Shortened (“Dash”) Protocol: A NeuroStar® W. Scott West
64 Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment Resistant Depression (SAINT-TRD): results from a double-blinded, randomized, and controlled trial Angela Leah Phillips
65 Theta Burst Compared to Standard Repetitive Transcranial Magnetic Stimulation For Major Depressive Disorder At A Suburban Tertiary Clinic Amelia Hess
66 Effectiveness of multiple rTMS treatments per day for Depressive Disorder at Living Mind, UK Arghya Sarkhel
68 Transcranial Magnetic Stimulation for Neuropathic Pain: Treating Comorbid Pain and Depression Joshua Kuluva
69 Increased Absolute Power in the Left Prefrontal Cortex with TMS Treatment For Complex Depression Laura Viner
70 Outcomes and feasibility from the first TMS specific web-based intervention Michelle Cochran
71 Clinical Outcomes using dTMS targeting the DMPFC-ACC in Treatment-Resistant OCD Richard A. Bermudes
72 The Case for Incorporating EEG in Clinical TMS Practice Shelly Menolascino

Acknowledgment of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must review each poster chosen and take up to 15 minutes to absorb the information and complete an evaluation form to receive a certificate of completion.

Complete all posters you wish to view before completing the evaluation.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.  

Physicians

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this enduring material for a maximum of 14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Objectives - After Attending This Program You Should Be Able To

  1. Identify evidence for various TMS treatment approaches compared to standard TMS approach
  2. Discuss the effectiveness of TMS in various populations and settings
  3. Discuss predictive biomarkers and/or clinical markers of response to repetitive transcranial magnetic stimulation (rTMS) treatment

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed on the website. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Name

Last Name

Commercial Interest: Relationship

Linda

Carpenter

Janssen: Consultant, Neuronetics: Research Grant Overall Principal Investigator, Affect Neuro: Consultant, Neosync: Research Grant Site Principal Investigator, Affect Neuro: Research Grant Overall Principal Investigator, Janssen: Research Grant Site Principal Investigator, Nexstim: Research Equipment Loan, Neuronetics: Research Equipment Loan, Neuronetics: Consultant, Sage Therapeutics: Consultant, Neurolief: Consultant

Roman

Gersner

BrainsWay: Employee*

Geoff

Grammer

Greenbrook TMS: Scientific/Medical Advisory Board Member, Greenbrook TMS: Employee, Neuronetics: Stock Shareholder, Brainsway: Research Grant Site Principal Investigator

Natalie

Haustrup

Eli Lilly: Employee*

Karen

Heart

Neuronetics: Employee*

Joshua

Kuluva

Sunovion: Speakers Bureau

Joshua

Kuluva

Sunovion: Speakers Bureau

Owen

Muir

Brainsway: Research Funding, speaker

Kenneth

Pages

Neuronetics:Speakers Bureau

Randy

Pardell

Neuronetics: Other

Debra

Stultz

Jazz Pharmaceticuls: Speakers Bureau, Harmony Biosciences: Speakers Bureau

Aron

Tendler

Brainsway Ltd.: Consultant, Advanced Mental Health Care: Stock Shareholder, Aron Tendler MD PA: Stock Shareholder, Brainsway Ltd.: Stock Shareholder

Jeff

Voigt

Magstim: Consultant


* Employee relationships with commercial interest organizations were vetted and found to be unbiased.